Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial

摘要: Background: Decrease of circulating tumor cells (CTC) during treatment is an independent prognostic factor in metastatic breast cancer (MBC). We specifically evaluated the impact CTC on brain metastasis outcome. Methods: HER2-positive MBC with not previously treated whole-brain radiotherapy received firstline combination lapatinib and capecitabine a phase II study. were detected at baseline day 21 (CellSearch). Results: Median follow-up 44 analyzed patients was 21.2 months. The central nervous system objective response (CNS-OR) rate 66%. At baseline, 20 41 assessable for (49%) had ≥1 (range 1–301, median 3) 9 (22%) ≥5 CTC. 21, 7 38 (18%) ≥ 1C TC (P = 0.006, versus baseline), disappeared 11 patients. CNS-OR significantly higher no [25 31 (80%) 2 (29%), P= 0.01]. 1-year overall survival 83.9% 42.9% (P= 0.02). Conclusions: This first report showing correlation between CNS response, outcome early clearance under targeted HER2+ MBC. Clinical Trials number: NCT00967031.